Peptide
Selank
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
A Russian synthetic tuftsin analog used clinically as a non-sedating anxiolytic. Raises GABA tone, BDNF, and enkephalin activity without benzodiazepine-style dependence.
Summary Can Selank reduce anxiety without the usual calming-drug side effects? Show / hide ↓
Selank is a synthetic peptide, a short chain of amino acids, developed in Russia as a prescription anxiety treatment. Short Russian studies lasting about 14 days found anxiety relief similar to medazepam, a benzodiazepine, which is a type of sedating anxiety medicine. It may influence GABA, a brain chemical involved in calming, but its long-term effects and wider uses remain unclear. Reported side effects include nasal irritation, occasional drowsiness at higher amounts, and mild stomach upset; no dependence or withdrawal has been documented, but this does not prove long-term safety. Community users commonly take 300 to 900 micrograms through the nose daily, but this use and combining it with Semax have not been formally tested.
What this means for you: Selank has some encouraging short-term Russian research, but the overall evidence is limited. It should not be viewed as a proven long-term replacement for established anxiety treatments.
early evidenceSelank is the anxiolytic member of the Russian regulatory-peptide family, paired conceptually with Semax as the nootropic. It is approved in Russia for generalized anxiety and adjustment disorders, with roughly two decades of prescription-level clinical use behind it. As with Semax, the international regulatory footprint is minimal and English-language trial data is sparse.
Mechanistically, Selank works through multiple pathways in parallel. It raises hippocampal and cortical BDNF and NGF, similar to Semax but with a different downstream pattern. It modulates GABA-A receptor sensitivity and increases enkephalin activity, producing anxiolytic effects without benzodiazepine binding. It also modulates monoamine turnover, particularly serotonin, and has been reported to reduce inflammatory cytokines in some contexts.
Russian clinical trials in generalized anxiety disorder have shown roughly equivalent efficacy to medazepam (a benzodiazepine) over 14 day courses, without the sedation, cognitive dulling, or dependence potential characteristic of benzodiazepines. This is the key clinical selling point: an anxiolytic that works without the side-effect burden of the benzodiazepine class.
Inside the biohacker community, Selank is used for acute anxiety, stress reduction, and social-anxiety symptoms, often at 300 to 900 mcg intranasal per day. It is frequently stacked with Semax, with Semax in the morning for drive and focus and Selank later for stress modulation. Combined use has not been studied in a formal trial.
Safety in Russian post-marketing data is reassuring. Reported side effects are minimal: mild nasal irritation, occasional transient drowsiness at higher doses, rare mild GI upset. No dependence or withdrawal syndrome has been documented, which is the mechanistic advantage over benzodiazepines. Long-term effects on baseline GABAergic tone are not well characterized.
Our position: Selank sits at Tier 3 for anxiety indications based on Russian clinical evidence and mechanism. Tier 4 for the community uses (general stress reduction, social confidence, sleep quality) which have not been formally trialed. As with Semax, the mechanism is genuine and the Russian clinical base is more substantial than the English-language literature suggests.
Selank has one small Russian comparator trial against an anti-anxiety drug and was not part of the July 2026 PCAC review, leaving its US compounding status less defined than its stablemate Semax.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Not reviewed at July 2026 PCAC meeting. The meeting covered seven substances: BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax, and Emideltide (DSIP); Selank was not among them (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).
US status
Not FDA approved for any indication; not on the 503A Bulks List. It falls under the same general research-chemical/gray-market access pattern as Semax, but without a 2026 PCAC vote to reference for its specific regulatory trajectory.
EU status
Not authorised for human use in EU as of 2026; used clinically in Russia in the same regulatory environment as Semax.
Best-supported claim
A 62-patient Russian comparator study found selank produced anxiolytic effects statistically similar to medazepam in patients with generalized anxiety disorder and neurasthenia, with treatment-associated increases in blood leu-enkephalin activity that correlated with symptom improvement (https://pubmed.ncbi.nlm.nih.gov/18454096/). This is real, published human outcome data in a clinical psychiatric population, comparing Selank against an active drug rather than placebo, which is a meaningfully different (and in some ways stronger) design than most peptides on this list have.
Not supported by the evidence base
Nootropic vendors market Selank as a general-population anxiety and focus supplement for healthy adults using language implying broad efficacy (https://thepeptidetoolkit.com/selank-guide/). The only published human trial studied patients with diagnosed generalized anxiety disorder or neurasthenia, not healthy people seeking a cognitive edge. No placebo-controlled RCT exists; the 2008 study compared Selank only to an active benzodiazepine-class drug, so there is no evidence isolating Selank's effect from a placebo response in that trial.
Typical usage
250-500 mcg intranasal, once or twice daily, in wellness self-administration protocols; the published clinical study used intranasal and oral routes in diagnosed anxiety patients, and no standardized wellness dose has been clinically validated.
Safety
The 2008 comparator study reported clinical improvement without describing a detailed adverse-event profile in available English-language summaries (https://pubmed.ncbi.nlm.nih.gov/18454096/). As with Semax, Selank was not part of the 2026 PCAC review, so there is no current FDA characterization of its immunogenicity or compounding risk on record. There is no safety data in pregnant people, children, or people with psychiatric comorbidities beyond generalized anxiety disorder. Anyone on benzodiazepines or other anxiolytics should avoid combining them with Selank without medical supervision given overlapping mechanisms.
Interactions worth flagging
- No formal drug-interaction studies exist outside the single Russian comparator trial
- Theoretical additive sedative or anxiolytic effect when combined with benzodiazepines (e.g., medazepam)
- Commonly stacked with Semax in nootropic protocols with no studied combination safety data
Three recent studies to know
-
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Selank produced anxiolytic effects similar to medazepam with additional antiasthenic effects and treatment-associated changes in blood enkephalin activity.
Read study → -
What the FDA's July 2026 PCAC Peptide Review Decided
The July 2026 PCAC review covered seven peptides; Selank was not among the substances reviewed or voted on.
Read study → -
Selank: Research, Evidence, Dosing & Safety
Summarizes that Selank's human evidence base rests on a small number of older Russian clinical studies with no Western replication as of 2026.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.